Mosunetuzumab

ATC L01FX25 · 8 markets · 19 records

Mosunetuzumab 8 markets · 19 records Forms

US 4 records · 4 strengths

1 mgliquidLunsumio also in CA
30 mg/30 mLliquidLunsumio
45 mginjectionLunsumio Velo
5 mg/0.5 mLinjectionLunsumio Velo

CA 3 records · 3 strengths

1 mgliquidLunsumio also in US
45 mgliquidLUNSUMIO SC
5 mgliquidLUNSUMIO SC

GB 2 records · 2 strengths

30 mg/30 mLinjectionLunsumio 1mg/1ml concentrate for solution for infusion vials also in SG
1 mg/1 mLinjectionLunsumio 1mg/1ml concentrate for solution for infusion vials also in ES

SG 2 records · 2 strengths

30 mg/30 mLinjectionLunsumio concentrate for solution for infusion also in GB
1 mg/mLinjectionLUNSUMIO CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML

ES 2 records · 1 strengths

1 mg/1 mLinjectionLunsumio also in GB

HK 2 records · 1 strengths

Records without a stated strength · 1 Lunsumio concentrate for solution for infusion

TW 1 records · 1 strengths

Records without a stated strength · 1 Lunsumio concentrate for solution for infusion、癌舒妥注射劑

EU 1 records · 1 strengths

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

Records without a stated strength · 1 Lunsumio

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.